London
· Delayed Price · Currency is GBP · Price in SEK BioInvent International AB Statistics
Total Valuation
BioInvent International AB has a market cap or net worth of GBP 137.75 million. The enterprise value is 68.97 million.
| Market Cap | 137.75M |
| Enterprise Value | 68.97M |
Important Dates
The next estimated earnings date is Thursday, February 27, 2025.
| Earnings Date | Feb 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.96% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 33.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.29 |
| EV / Sales | 24.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.56 |
Financial Position
The company has a current ratio of 13.29, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.29 |
| Quick Ratio | 13.16 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -715.88 |
Financial Efficiency
Return on equity (ROE) is -34.01% and return on invested capital (ROIC) is -23.33%.
| Return on Equity (ROE) | -34.01% |
| Return on Assets (ROA) | -22.21% |
| Return on Capital (ROIC) | -23.33% |
| Revenue Per Employee | 24,715 |
| Profits Per Employee | -262,047 |
| Employee Count | 111 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +166.26% in the last 52 weeks. The beta is 0.38, so BioInvent International AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | +166.26% |
| 50-Day Moving Average | 40.61 |
| 200-Day Moving Average | 37.22 |
| Relative Strength Index (RSI) | 21.08 |
| Average Volume (20 Days) | 521 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioInvent International AB had revenue of GBP 2.84 million and -30.14 million in losses. Loss per share was -0.46.
| Revenue | 2.84M |
| Gross Profit | 2.84M |
| Operating Income | -33.60M |
| Pretax Income | -30.11M |
| Net Income | -30.14M |
| EBITDA | -32.75M |
| EBIT | -33.60M |
| Loss Per Share | -0.46 |
Balance Sheet
The company has 69.89 million in cash and 1.25 million in debt, giving a net cash position of 68.64 million.
| Cash & Cash Equivalents | 69.89M |
| Total Debt | 1.25M |
| Net Cash | 68.64M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 73.79M |
| Book Value Per Share | 1.12 |
| Working Capital | 68.78M |
Cash Flow
In the last 12 months, operating cash flow was -26.08 million and capital expenditures -878,268, giving a free cash flow of -26.96 million.
| Operating Cash Flow | -26.08M |
| Capital Expenditures | -878,268 |
| Free Cash Flow | -26.96M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,182.13% |
| Pretax Margin | -1,059.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioInvent International AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.96% |
| Shareholder Yield | -0.96% |
| Earnings Yield | -21.88% |
| FCF Yield | -19.57% |
Stock Splits
The last stock split was on December 14, 2020. It was a reverse split with a ratio of 0.04.
| Last Split Date | Dec 14, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |